PERIPHERAL ISCHEMIC RETINAL PHOTOCOAGULATION IN ADDITION TO INTRAVITREAL BEVACIZUMAB VERSUS INTRAVITREAL BEVACIZUMAB ALONE FOR THE TREATMENT OF MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION: A Randomized Double-Masked Controlled Clinical Trial.
Adult
Aged
Angiogenesis Inhibitors
/ administration & dosage
Bevacizumab
/ administration & dosage
Double-Blind Method
Female
Fluorescein Angiography
/ methods
Follow-Up Studies
Fundus Oculi
Humans
Intravitreal Injections
Laser Coagulation
/ methods
Macular Edema
/ diagnosis
Male
Middle Aged
Prospective Studies
Receptors, Vascular Endothelial Growth Factor
/ antagonists & inhibitors
Retinal Vein Occlusion
/ complications
Tomography, Optical Coherence
/ methods
Visual Acuity
Journal
Retina (Philadelphia, Pa.)
ISSN: 1539-2864
Titre abrégé: Retina
Pays: United States
ID NLM: 8309919
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
pubmed:
4
6
2019
medline:
5
5
2021
entrez:
4
6
2019
Statut:
ppublish
Résumé
To investigate the effects of peripheral ischemic retinal photocoagulation in addition to intravitreal bevacizumab (IVB) in the treatment of macular edema due to ischemic central retinal vein occlusion. Forty-eight eyes of 48 treatment-naive patients were randomly selected and divided into 2 groups. Group A comprised 24 eyes that were treated with three consecutive monthly injections of IVB, and Group B comprised 24 eyes that were treated with IVB plus photocoagulation of the peripheral nonperfused retina. Further IVB injections were administered as needed in both groups. Monthly follow-up was conducted for 9 months after the first injection. The data of 46 patients were analyzed. Best-corrected visual acuity changes from the fourth to eighth month follow-up in comparison with the baseline were significantly higher in Group B (P = 0.002-0.044-0.002-0.002-0.012). In addition, significant differences were observed in central macular thickness in Group B throughout the study period (all P < 0.001). Group B required less frequent IVB injections during the 9-month study period. Photocoagulation of the retinal nonperfused area in patients with macular edema because of central retinal vein occlusion might amplify the beneficial effects of IVB on best-corrected visual acuity and central macular thickness and reduce the frequency of IVB injection.
Identifiants
pubmed: 31157710
doi: 10.1097/IAE.0000000000002573
pii: 00006982-202006000-00014
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Bevacizumab
2S9ZZM9Q9V
Receptors, Vascular Endothelial Growth Factor
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1110-1117Références
Cugati S, Wang JJ, Knudtson MD, et al. Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts. Ophthalmology 2007;114:520–524.
Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol 1994;117:429–441.
Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 1996;114:1243–1247.
Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the beaver dam eye study. Trans Am Ophthalmol Soc 2000;98:133–3; discussion 41–43.
Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 2002;120:1644–1650.
Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 5. Arch Ophthalmol 2009;127:1101–1114.
Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134–1146.
Epstein DL, Algvere PV, von Wendt G, et al. Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study. Ophthalmology 2012;119:1184–1189.
Boyer D, Heier J, Brown DM, et al. Vascular endothelial growth factor trap-eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology 2012;119:1024–1032.
Holz FG, Roider J, Ogura Y, et al. VEGF trap-eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol 2013;97:278–284.
Korobelnik JF, Holz FG, Roider J, et al. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 galileo study. Ophthalmology 2014;121:202–208.
Matsumoto Y, Freund KB, Peiretti E, et al. Rebound macular edema following bevacizumab (avastin) therapy for retinal venous occlusive disease. Retina 2007;27:426–431.
Moisseiev E, Waisbourd M, Ben-Artsi E, et al. Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes. Graefes Arch Clin Exp Ophthalmol 2014;252:331–337.
Gozawa M, Takamura Y, Miyake S, et al. Photocoagulation of the retinal nonperfusion area prevents the expression of the vascular endothelial growth factor in an animal model. Invest Ophthalmol Vis Sci 2017;58:5946–5953.
Rehak M, Tilgner E, Franke A, et al. Early peripheral laser photocoagulation of nonperfused retina improves vision in patients with central retinal vein occlusion (results of a proof of concept study). Graefes Arch Clin Exp Ophthalmol 2014;252:745–752.
Tultseva SN, Astakhov YS, Novikov SA, et al. Alternative ways to optimize treatment for retinal vein occlusion with peripheral capillary non-perfusion: a pilot study. Arq Bras Oftalmol 2017;80:224–228.
Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The central vein occlusion study group m report. Ophthalmology 1995;102:1425–1433.
Campochiaro PA, Hafiz G, Mir TA, et al. Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: the RELATE trial. Ophthalmology 2015;122:1426–1437.
Wykoff CC, Ou WC, Wang R, et al. Peripheral laser for recalcitrant macular edema owing to retinal vein occlusion: the WAVE trial. Ophthalmology 2017;124:919–921.
Abri Aghdam K, Reznicek L, Soltan Sanjari M, et al. Anti-VEGF treatment and peripheral retinal nonperfusion in patients with central retinal vein occlusion. Clin Ophthalmol 2017;11:331–336.